NO20092146L - Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en 5-HT1A-agonist, i behandlingen av seksuell dysfunksjon - Google Patents

Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en 5-HT1A-agonist, i behandlingen av seksuell dysfunksjon

Info

Publication number
NO20092146L
NO20092146L NO20092146A NO20092146A NO20092146L NO 20092146 L NO20092146 L NO 20092146L NO 20092146 A NO20092146 A NO 20092146A NO 20092146 A NO20092146 A NO 20092146A NO 20092146 L NO20092146 L NO 20092146L
Authority
NO
Norway
Prior art keywords
optionally
combination
sexual dysfunction
androstiol
alfa
Prior art date
Application number
NO20092146A
Other languages
English (en)
Norwegian (no)
Inventor
Jan Johan Adriaan Tuiten
Johannes Martinus Maria Bloemers
Robertus Petrus Johannes De Lange
Original Assignee
Emotional Brain Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emotional Brain Bv filed Critical Emotional Brain Bv
Publication of NO20092146L publication Critical patent/NO20092146L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NO20092146A 2006-11-03 2009-06-03 Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en 5-HT1A-agonist, i behandlingen av seksuell dysfunksjon NO20092146L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06076976A EP1925307A1 (en) 2006-11-03 2006-11-03 Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
PCT/NL2007/050535 WO2008054215A2 (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
NO20092146L true NO20092146L (no) 2009-07-21

Family

ID=37846101

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20092146A NO20092146L (no) 2006-11-03 2009-06-03 Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en 5-HT1A-agonist, i behandlingen av seksuell dysfunksjon
NO20092143A NO343597B1 (no) 2006-11-03 2009-06-03 Anvendelse av testosteron og en 5-HT1A-agonist ved behandling av seksuell dysfunksjon
NO20092145A NO20092145L (no) 2006-11-03 2009-06-03 Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en PDES-inhibitor, i behandlingen av seksuell dysfunksjon

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20092143A NO343597B1 (no) 2006-11-03 2009-06-03 Anvendelse av testosteron og en 5-HT1A-agonist ved behandling av seksuell dysfunksjon
NO20092145A NO20092145L (no) 2006-11-03 2009-06-03 Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en PDES-inhibitor, i behandlingen av seksuell dysfunksjon

Country Status (28)

Country Link
US (10) US8575139B2 (xx)
EP (5) EP1925307A1 (xx)
JP (8) JP2010509211A (xx)
KR (6) KR20090111803A (xx)
CN (6) CN103599536A (xx)
AU (3) AU2007314736B2 (xx)
BR (3) BRPI0717963A2 (xx)
CA (3) CA2668320C (xx)
CY (1) CY1117191T1 (xx)
DK (1) DK2086544T3 (xx)
ES (1) ES2561946T3 (xx)
HK (1) HK1135038A1 (xx)
HR (1) HRP20160108T1 (xx)
HU (1) HUE026752T2 (xx)
IL (5) IL198459A (xx)
ME (1) ME02410B (xx)
MX (3) MX2009004695A (xx)
NO (3) NO20092146L (xx)
NZ (3) NZ577390A (xx)
PH (2) PH12014501440A1 (xx)
PL (1) PL2086544T3 (xx)
PT (1) PT2086544E (xx)
RS (1) RS54541B1 (xx)
RU (4) RU2464027C2 (xx)
SI (1) SI2086544T1 (xx)
UA (4) UA103592C2 (xx)
WO (3) WO2008054213A2 (xx)
ZA (3) ZA200903837B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1750766T1 (sl) 2004-05-11 2013-11-29 Emotional Brain B.V. Farmacevtske formulacije in njihove uporabe pri zdravljenju spolne disfunkcije pri Ĺľenskah
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
JP6121990B2 (ja) * 2011-05-13 2017-04-26 イービー アイピー ハイブリタブス ビー．ブイ． 薬物送達システム
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP5828923B2 (ja) 2014-01-30 2015-12-09 国立大学法人高知大学 ニッケル粉の製造方法
JP5936783B2 (ja) 2014-02-21 2016-06-22 国立大学法人高知大学 ニッケル粉の製造方法
JP6406613B2 (ja) 2014-04-15 2018-10-17 住友金属鉱山株式会社 含有する炭素及び硫黄の濃度を低減するニッケル粉の製造方法
CN103947533B (zh) * 2014-05-15 2015-12-16 青岛理工大学 生长环境可控的磁化水工厂化豆芽菜生产系统
RU2600845C2 (ru) 2014-07-04 2016-10-27 Общество С Ограниченной Ответственностью "Консорциум-Пик" Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3251436A (en) * 1965-03-16 1966-05-17 Dayton Steel Foundry Co Spot-type disk brake
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
ZA848005B (en) 1983-10-17 1985-05-29 Duphar Int Res Blood-pressure lowering piperazine derivatives
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US5015646A (en) 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
US4877774A (en) 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
AU694125B2 (en) 1994-06-02 1998-07-16 Dan Riga Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof
RU2152787C2 (ru) 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
AU4844396A (en) 1995-03-01 1996-09-18 Kyowa Hakko Kogyo Co. Ltd. Imidazoquinazoline derivatives
SK124397A3 (en) 1995-03-14 1998-12-02 Vivus Inc Method and kit for preventing erectile dysfunction
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
AU5671496A (en) * 1995-05-15 1996-11-29 Beth Israel Hospital Use of dihydrotestosterone compounds for treating male sexual dysfunction
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
JP2002505676A (ja) * 1997-06-23 2002-02-19 クイーンズ ユニバーシティー アット キングストン 微量投与療法
WO1999021562A1 (en) 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6246436B1 (en) 1997-11-03 2001-06-12 Agilent Technologies, Inc Adjustable gain active pixel sensor
TW542719B (en) 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6613768B1 (en) 1999-04-30 2003-09-02 Lilly Icos Llc Treatment of female arousal disorder
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US6632419B2 (en) 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
NZ516223A (en) 1999-06-17 2003-08-29 Pharmacia Ab Use of growth hormone (hGH) for the treatment of sexual dysfunction
RU2180591C2 (ru) 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
DE10016548A1 (de) * 2000-04-03 2001-10-11 Bayer Ag Polyurethan-Dispersionen
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
MXPA03001858A (es) 2000-08-30 2004-05-21 Unimed Pharmaceuticals Inc Metodo para el tratamiento de la disfuncion erectil e incremento en el libido del hombre.
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
CZ299411B6 (cs) 2000-09-29 2008-07-16 Solvay Pharmaceuticals B. V. Farmaceutický matricový prípravek vytvárející hydrofilní gel a zpusob výroby tohoto prípravku
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
EP1347750A1 (en) * 2000-12-15 2003-10-01 Pfizer Limited Treatment of male sexual dysfunction
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
WO2002069906A2 (en) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
GEP20063783B (en) 2001-03-28 2006-04-10 Pfizer N-Phenpropylcyclopentyl-Substituted Glutaramide Derivatives as Inhibitors of Neutral Endopeptidase Enzyme (NEP) for Treating Female Sexual Dysfunction (FSAD)
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US20030027804A1 (en) 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
CA2532252A1 (en) * 2003-07-16 2005-01-27 Pfizer Inc. Treatment of sexual dysfunction
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
PT1530965E (pt) 2003-11-11 2006-05-31 Udo Mattern Sistema de administracao de libertacao controlada de hormonas sexuais para aplicacao nasal
WO2005094827A1 (en) * 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methods for treating sexual dysfunction
NZ551340A (en) 2004-04-22 2010-10-29 Boehringer Ingelheim Int Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder
SI1750766T1 (sl) 2004-05-11 2013-11-29 Emotional Brain B.V. Farmacevtske formulacije in njihove uporabe pri zdravljenju spolne disfunkcije pri Ĺľenskah
KR20080016552A (ko) 2005-04-13 2008-02-21 유니메드 파마슈티칼스, 인크. 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법
WO2006127057A1 (en) 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
WO2007054791A2 (en) * 2005-11-08 2007-05-18 L'oréal Androgen glucuronides as markers of androgenic activity
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
ME02275B (me) 2007-11-28 2016-02-20 Ucb Pharma Gmbh Polimorfni oblik rotigotina

Also Published As

Publication number Publication date
RS54541B1 (en) 2016-06-30
US8648060B2 (en) 2014-02-11
PL2086544T3 (pl) 2016-07-29
MX2009004693A (es) 2009-06-05
CN101573119A (zh) 2009-11-04
WO2008054215A3 (en) 2009-04-09
KR20090111802A (ko) 2009-10-27
WO2008054215A2 (en) 2008-05-08
MX2009004695A (es) 2009-06-05
IL198461A (en) 2017-08-31
ME02410B (me) 2016-09-20
US8653051B2 (en) 2014-02-18
RU2491073C2 (ru) 2013-08-27
AU2007314734A1 (en) 2008-05-08
CY1117191T1 (el) 2017-04-05
NZ577393A (en) 2012-11-30
BRPI0717856A2 (pt) 2013-10-29
NO20092143L (no) 2009-07-02
WO2008054214A3 (en) 2009-04-09
US20120277200A1 (en) 2012-11-01
US8669242B2 (en) 2014-03-11
KR20090115113A (ko) 2009-11-04
RU2009120990A (ru) 2010-12-10
JP2010509213A (ja) 2010-03-25
CA2668320A1 (en) 2008-05-08
WO2008054214A2 (en) 2008-05-08
DK2086544T3 (en) 2016-02-08
ZA200903837B (en) 2010-08-25
AU2007314736A1 (en) 2008-05-08
HUE026752T2 (en) 2016-07-28
UA100119C2 (uk) 2012-11-26
WO2008054213A2 (en) 2008-05-08
US9211334B2 (en) 2015-12-15
JP2014055142A (ja) 2014-03-27
NZ577392A (en) 2012-11-30
AU2007314735A1 (en) 2008-05-08
IL248563A0 (en) 2016-12-29
PT2086544E (pt) 2016-03-17
KR101796887B1 (ko) 2017-11-10
JP2010509212A (ja) 2010-03-25
EP1925307A1 (en) 2008-05-28
AU2007314734B2 (en) 2014-01-30
US8575139B2 (en) 2013-11-05
US20190262359A1 (en) 2019-08-29
IL248563B (en) 2018-11-29
HRP20160108T1 (hr) 2016-03-25
IL198459A0 (en) 2010-02-17
IL198460A (en) 2016-11-30
EP2086544B1 (en) 2015-12-23
RU2009120988A (ru) 2010-12-10
CN101557812A (zh) 2009-10-14
US10314848B2 (en) 2019-06-11
US20170157142A1 (en) 2017-06-08
US20160082018A1 (en) 2016-03-24
RU2463054C2 (ru) 2012-10-10
HK1135038A1 (en) 2010-05-28
CA2668317C (en) 2016-02-09
IL198461A0 (en) 2010-02-17
US20140121189A1 (en) 2014-05-01
IL237786A0 (en) 2015-05-31
KR101578224B1 (ko) 2015-12-16
RU2646447C2 (ru) 2018-03-05
EP2086545A2 (en) 2009-08-12
PH12014501821B1 (en) 2016-02-01
KR20160124246A (ko) 2016-10-26
EP2086548A2 (en) 2009-08-12
NO20092145L (no) 2009-07-21
JP2017132809A (ja) 2017-08-03
UA101948C2 (uk) 2013-05-27
WO2008054213A3 (en) 2009-04-09
JP5748238B2 (ja) 2015-07-15
NO343597B1 (no) 2019-04-08
AU2007314736B2 (en) 2014-01-23
CA2668320C (en) 2014-06-10
US20100160270A1 (en) 2010-06-24
BRPI0718396A2 (pt) 2013-11-26
CN104524580A (zh) 2015-04-22
NZ577390A (en) 2012-12-21
CA2668316C (en) 2014-06-10
CA2668317A1 (en) 2008-05-08
SI2086544T1 (sl) 2016-04-29
RU2009120992A (ru) 2010-12-10
JP2014001235A (ja) 2014-01-09
UA103592C2 (uk) 2013-11-11
AU2007314735B2 (en) 2014-01-16
ZA200903836B (en) 2010-08-25
CN101563086B (zh) 2013-11-27
KR20090111803A (ko) 2009-10-27
JP2014111608A (ja) 2014-06-19
JP2015157849A (ja) 2015-09-03
CN103599536A (zh) 2014-02-26
KR20150099620A (ko) 2015-08-31
US20100152145A1 (en) 2010-06-17
RU2464027C2 (ru) 2012-10-20
BRPI0717963A2 (pt) 2013-11-05
CN103381270A (zh) 2013-11-06
PH12014501821A1 (en) 2016-02-01
UA115647C2 (uk) 2017-12-11
IL198459A (en) 2016-11-30
MX2009004696A (es) 2009-06-05
EP2086544A2 (en) 2009-08-12
US20140038929A1 (en) 2014-02-06
RU2012125827A (ru) 2013-12-27
US9597335B2 (en) 2017-03-21
PH12014501440A1 (en) 2016-02-01
JP2010509211A (ja) 2010-03-25
US20100093680A1 (en) 2010-04-15
JP6357131B2 (ja) 2018-07-11
ES2561946T3 (es) 2016-03-01
CN101563086A (zh) 2009-10-21
KR20150038251A (ko) 2015-04-08
ZA200903835B (en) 2010-10-27
EP2937086A1 (en) 2015-10-28
CA2668316A1 (en) 2008-05-08
IL198460A0 (en) 2010-02-17
US20140121190A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
NO20092146L (no) Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en 5-HT1A-agonist, i behandlingen av seksuell dysfunksjon
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
GB0515353D0 (en) Food
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
EP1740183B8 (en) Novel use for pde5 inhibitors
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
MX2009008511A (es) Reduccion de efectos secundarios de tramadol.
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
NO20075662L (no) Roflumilast for behandlingen av pulmonal hypertensjon
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
RS54140B1 (en) USE OF 24-ORDER
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
WO2006102126A3 (en) Inhibitors of isoprenylcysteine carboxyl methyltransferase
ECSP055715A (es) Utilizacion de pirimetanilo en patogenos resistentes
AU311277S (en) Hammer
MXPA05008092A (es) Composicion farmaceutica antiviral.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: EB IP LYBRIDOS B.V., NL

FC2A Withdrawal, rejection or dismissal of laid open patent application